
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IRAK-4 result in IRAK4 deficiency and recurrent invasive pneumococcal disease. It phosphorylates E3 ubiquitin ligases Pellino proteins to promote pellino-mediated polyubiquitination of IRAK1. Ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. MAP3K7/TAK1 activates IKKs leading to NF-kappa-B nuclear translocation and activation.
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) pipeline Target constitutes close to 24 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 8, 10 and 2 respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology, Gastrointestinal, Metabolic Disorders, Cardiovascular, Central Nervous System, Infectious Disease, Musculoskeletal Disorders and Undisclosed which include indications Rheumatoid Arthritis, Inflammation, Atopic Dermatitis (Atopic Eczema), Myelodysplastic Syndrome, Autoimmune Disorders, Diffuse Large B-Cell Lymphoma, Psoriasis, Chronic Myelomonocytic Leukemia (CMML), Follicular Lymphoma, Hidradenitis Suppurativa, Inflammatory Bowel Disease, Lymphoma, Unspecified Cancer, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Coronavirus Disease 2019 (COVID-19) Pneumonia, Cutaneous Lupus Erythematosus, Diabetic Nephropathy, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Gouty Arthritis (Gout), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Lupus Erythematosus, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Multiple Sclerosis, Pancreatic Ductal Adenocarcinoma, Primary CNS Lymphoma, Rosacea, Solid Tumor, Systemic Lupus Erythematosus, Type 1 Diabetes (Juvenile Diabetes) and Unspecified.
The latest report Interleukin 1 Receptor Associated Kinase 4 - Drugs In Development, 2022, outlays comprehensive information on the Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IRAK-4 result in IRAK4 deficiency and recurrent invasive pneumococcal disease. It phosphorylates E3 ubiquitin ligases Pellino proteins to promote pellino-mediated polyubiquitination of IRAK1. Ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. MAP3K7/TAK1 activates IKKs leading to NF-kappa-B nuclear translocation and activation.
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) pipeline Target constitutes close to 24 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 8, 10 and 2 respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology, Gastrointestinal, Metabolic Disorders, Cardiovascular, Central Nervous System, Infectious Disease, Musculoskeletal Disorders and Undisclosed which include indications Rheumatoid Arthritis, Inflammation, Atopic Dermatitis (Atopic Eczema), Myelodysplastic Syndrome, Autoimmune Disorders, Diffuse Large B-Cell Lymphoma, Psoriasis, Chronic Myelomonocytic Leukemia (CMML), Follicular Lymphoma, Hidradenitis Suppurativa, Inflammatory Bowel Disease, Lymphoma, Unspecified Cancer, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Coronavirus Disease 2019 (COVID-19) Pneumonia, Cutaneous Lupus Erythematosus, Diabetic Nephropathy, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Gouty Arthritis (Gout), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Lupus Erythematosus, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Multiple Sclerosis, Pancreatic Ductal Adenocarcinoma, Primary CNS Lymphoma, Rosacea, Solid Tumor, Systemic Lupus Erythematosus, Type 1 Diabetes (Juvenile Diabetes) and Unspecified.
The latest report Interleukin 1 Receptor Associated Kinase 4 - Drugs In Development, 2022, outlays comprehensive information on the Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)
- The report reviews Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
84 Pages
- Introduction
- Global Markets Direct Report Coverage
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) – Overview
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) – Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) – Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) – Companies Involved in Therapeutics Development
- Asahi Kasei Pharma Corp
- Astellas Pharma Inc
- AstraZeneca Plc
- Aurigene Discovery Technologies Ltd
- Bayer AG
- Beijing Hanmi Pharmaceutical Co Ltd
- Bristol-Myers Squibb Co
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Emmaus Life Sciences Inc
- Evommune Inc
- Fresh Tracks Therapeutics Inc
- Gilead Sciences Inc
- Kurome Therapeutics Inc
- Kymera Therapeutics Inc
- Nyrada Inc
- Pfizer Inc
- Rigel Pharmaceuticals Inc
- TG Therapeutics Inc
- Xi'An Yufan Biotechnology Co Ltd
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) – Drug Profiles
- AK-179 – Drug Profile
- AS-2444697 – Drug Profile
- AZD-6793 – Drug Profile
- BAY-1830839 – Drug Profile
- BMS-986126 – Drug Profile
- emavusertib hydrochloride – Drug Profile
- EVO-101 – Drug Profile
- FRTX-02 – Drug Profile
- GS-5718 – Drug Profile
- IRAK4 – Drug Profile
- KM-10544 – Drug Profile
- KT-413 – Drug Profile
- KT-474 – Drug Profile
- R-289 – Drug Profile
- R-835 – Drug Profile
- Small Molecule to Inhibit IRAK4 for Rheumatoid Arthritis and Unspecified Cancer – Drug Profile
- Small Molecules 1 to Inhibit IRAK4 for Inflammation – Drug Profile
- Small Molecules to Inhibit IRAK1 and IRAK4 for Acute Myelocytic Leukemia and Myelodysplastic Syndrome – Drug Profile
- Small Molecules to Inhibit IRAK4 for Autoimmune Disorders, Cardiovascular Disease, Inflammation and Oncology – Drug Profile
- Small Molecules to Inhibit IRAK4 for Inflammation – Drug Profile
- TQH-3821 – Drug Profile
- zabedosertib – Drug Profile
- zimlovisertib – Drug Profile
- ZYF-0116 – Drug Profile
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) – Dormant Products
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) – Discontinued Products
- Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) – Product Development Milestones
- Featured News & Press Releases
- Dec 16, 2022: Rigel doses first subject in Phase Ib myelodysplastic syndromes trial
- Dec 12, 2022: Curis announces additional encouraging clinical data from TakeAim Leukemia study of emavusertib (CA-4948) in monotherapy R/R AML and hrMDS
- Dec 06, 2022: Kurome Therapeutics announces oral and poster presentations on dual IRAK1/4 inhibitors at American Society of Hematology Annual Meeting
- Dec 05, 2022: Curis to host webcast to discuss updated emavusertib clinical data in leukemia
- Dec 01, 2022: Kymera Therapeutics provides webcast information for December 14 Investor Event
- Nov 07, 2022: Curis announces presentation on Emavusertib at SITC 2022
- Oct 13, 2022: Kymera Therapeutics to hold investor webcast on December 14 to share clinical update on KT-413
- Oct 13, 2022: Kymera Therapeutics to hold investor webcast on December 14 to share clinical data from KT-474 phase I patient cohort
- Sep 28, 2022: Evommune initiates phase 2a proof-of-concept clinical trial to evaluate EVO101 in atopic dermatitis
- Sep 13, 2022: Fresh Tracks Therapeutics initiates Multiple Ascending Dose portion of phase 1 study of DYRK1A inhibitor FRTX-02
- Aug 30, 2022: FDA allows patient enrollment to resume in monotherapy dose escalation of emavusertib in TakeAim Leukemia Study
- Aug 18, 2022: FDA Lifts partial clinical hold on the TakeAim lymphoma study of emavusertib
- Jun 15, 2022: Kymera Therapeutics doses first patients in phase 1 oncology trial of IRAKIMiD degrader KT-413
- Jun 10, 2022: Curis announces presentations on biomarker development and emavusertib clinical data at the 2022 European Hematology Association (EHA) Hybrid Congress
- Jun 04, 2022: Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development by Stage of Development, 2022
- Table 2: Number of Products under Development by Therapy Areas, 2022
- Table 3: Number of Products under Development by Indications, 2022
- Table 4: Number of Products under Development by Indications, 2022 (Contd..1)
- Table 5: Number of Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022
- Table 7: Products under Development by Companies, 2022 (Contd..1)
- Table 8: Products under Development by Companies, 2022 (Contd..2)
- Table 9: Products under Development by Companies, 2022 (Contd..3)
- Table 10: Number of Products by Stage and Mechanism of Actions, 2022
- Table 11: Number of Products by Stage and Route of Administration, 2022
- Table 12: Number of Products by Stage and Molecule Type, 2022
- Table 13: Pipeline by Asahi Kasei Pharma Corp, 2022
- Table 14: Pipeline by Astellas Pharma Inc, 2022
- Table 15: Pipeline by AstraZeneca Plc, 2022
- Table 16: Pipeline by Aurigene Discovery Technologies Ltd, 2022
- Table 17: Pipeline by Bayer AG, 2022
- Table 18: Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, 2022
- Table 19: Pipeline by Bristol-Myers Squibb Co, 2022
- Table 20: Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
- Table 21: Pipeline by Emmaus Life Sciences Inc, 2022
- Table 22: Pipeline by Evommune Inc, 2022
- Table 23: Pipeline by Fresh Tracks Therapeutics Inc, 2022
- Table 24: Pipeline by Gilead Sciences Inc, 2022
- Table 25: Pipeline by Kurome Therapeutics Inc, 2022
- Table 26: Pipeline by Kymera Therapeutics Inc, 2022
- Table 27: Pipeline by Nyrada Inc, 2022
- Table 28: Pipeline by Pfizer Inc, 2022
- Table 29: Pipeline by Rigel Pharmaceuticals Inc, 2022
- Table 30: Pipeline by TG Therapeutics Inc, 2022
- Table 31: Pipeline by Xi'An Yufan Biotechnology Co Ltd, 2022
- Table 32: Dormant Products, 2022
- Table 33: Dormant Products, 2022 (Contd..1)
- Table 34: Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development by Stage of Development, 2022
- Figure 2: Number of Products under Development by Therapy Areas, 2022
- Figure 3: Number of Products under Development by Top 10 Indications, 2022
- Figure 4: Number of Products by Stage and Mechanism of Actions, 2022
- Figure 5: Number of Products by Routes of Administration, 2022
- Figure 6: Number of Products by Stage and Routes of Administration, 2022
- Figure 7: Number of Products by Stage and Molecule Type, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.